Abstract
We examined the association of TIMP-1 and TIMP-2 gene polymorphisms with the progression of chronic liver disease related to the hepatitis C virus (HCV). We used PCR to analyze 188 patients with HCV-related liver disease (95 with chronic hepatitis and 93 with cirrhosis) for TIMP-1 372 T/C and TIMP-2 –418 G/C polymorphisms. Comparing chronic hepatitis and cirrhosis, there were no significant differences in TIMP-1 and TIMP-2 gene polymorphisms. Among chronic hepatitis patients, TIMP-2 –418 G homozygotes showed significantly faster fibrosis progression than C carriers. Among cirrhotic patients, males with the TIMP-1 372 T allele developed cirrhosis at a younger age, and patients who were homozygous for the higher-transcription TIMP-2 –418 G allele had significantly lower serum albumin concentrations. These results suggest that faster progression of liver fibrosis could be associated with TIMP-2 –418 G homozygotes.
Similar content being viewed by others
References
Arthur MJP (2000) Fibrogenesis II: metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 279:G245–G249
Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115:3719–3727
Bekkaoui F, Poisson I, Crosby W, Cloney L, Duck P (1996) Cycling probe technology with RNase H attached to an oligonucleotide. Biotechniques 20:240–248
Bernardo MM, Fridman R (2003) TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J 374:739–745
De Clerck YA, Darville MI, Eeckhout Y, Rousseau GG (1994) Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinase-2 (TIMP-2). Gene 139:185–191
Duck P, Alvarado-Urbina G, Burdick B, Collier B (1990) Probe amplifier system based on chimeric cycling oligonucleotides. Biotechniques 9:142–148
Faisst S, Meyer S (1992) Compilation of vertebrate-encoded transcription factors. Nucleic Acids Res 20:3–26
Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J (2002) Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36:986–992
Friedman SL (2003) Liver fibrosis: from bench to bedside. J Hepatol 38:S38–S53
Hegab AE, Sakamoto T, Uchida Y, Nomura A, Ishii Y, Morishima Y, Mochizuki M, Kimura T, Saitoh W, Iizuka T, Kiwamoto T, Sekizawa K (2005) Promoter activity of human tissue inhibitor of metalloproteinase 2 gene with novel single nucleotide polymorphisms. Respirology 10:27–30
Hemmann S, Graf J, Roderfeld M, Roeb E (2007) Expression of MMPs and TIMPs in liver fibrosis: a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 46:955–975
Hinterseher I, Krex D, Kuhlisch E, Schmidt KG, Pilarsky C, Schneiders W, Pilarsky C, Schneiders W, Saeger HD, Bergert H (2007) Tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphisms in a Caucasian population with abdominal aortic aneurysm. World J Surg 31:2248–2254
Hirano K, Sakamoto T, Uchida Y, Morishima Y, Masuyama K, Ishii Y, Nomura A, Ohtsuka M, Sekizawa K (2001) Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 18:748–752
Indelicato M, Chiarenza V, Libra M, Malaponte G, Bevelacqua V, Marchini M, McCubrey JA, Stivala F, Scorza R, Mazzarino MC (2006) Analysis of TIMP-1 gene polymorphisms in Italian sclerodermic patients. J Clin Lab Anal 20:173–176
Kang S, Zhao X, Xing H, Wang N, Zhou R, Chen S, Li W, Zhao J, Duan Y, Sun D, Li Y (2008) Polymorphisms in the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 and the risk of human adenomyosis. Environ Mol Mutagen 49:226–231
Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y (2007) FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 45:297–306
Krex D, Röhl H, König IR, Ziegler A, Schackert HK, Schackert G (2003) Tissue inhibitor of metalloproteinases-1, -2 and -3 polymorphisms in a white population with intracranial aneurysms. Stroke 34:2817–2821
Marcellin P (2009) Hepatitis B and hepatitis C in 2009. Liver Int 29:S1–S8
Marcellin P, Asselah T, Boyer N (2002) Fibrosis and disease progression in hepatitis C. Hepatology 36:S47–S56
Meijer MJW, Mieremet-Ooms MAC, van Hogezand RA, Lamers CBHW, Hommes DW, Verspaget HW (2007) Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol 13:2960–2966
Murawaki Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H (1997) Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J Hepatol 26:1213–1219
Murawaki Y, Ikuta Y, Kawasaki H (1999) Clinical usefulness of serum tissue inhibitor of metalloproteinases (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1. Clin Chim Acta 281:109–120
Nie Q-H, Zhu C-L, Zhang Y-F, Yang J, Zhang J-C, Gao R-T (2010) Inhibitory effect of antisense oligonucleotide targeting TIMP-2 on immune-induced liver fibrosis. Dig Dis Sci 55:1286–1295
O-charoenrat P, Khantapura P (2006) The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol 42:257–267
Polette M, Birembaut P (1998) Membrane-type metalloproteinases in tumor invasion. Int J Biochem Cell Biol 30:1195–1202
Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C: the ObsVirC, MetaVir, CliniVir, and DosVirC groups. Lancet 349:825–832
Promrat K, McDermott DH, Gonzalez CM, Kleiner DE, Koziol DE, Lessie M, Merrell M, Soza A, Heller T, Ghany M, Park Y, Alter HJ, Hoofnagle JH, Murphy PM, Liang TJ (2003) Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 124:352–360
Wei JC, Lee HS, Chen WC, Shiu LJ, Yang SF, Wong RH (2009) Genetic polymorphisms of the matrix metalloproteinase-3 (MMP-3) and tissue inhibitors of matrix metalloproteinases-1 (TIMP-1) modulate the development of ankylosing spondylitis. Ann Rheum Dis 68:1781–1786
Wei S, Chen Y, Chung L, Nagase H, Brew K (2003) Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain. J Biol Chem 278:9831–9834
Yi YC, Chen M-K, Chen L-Y, Ho ES-C, Ying T-H, Wang P-H, Yang SF (2009) Genetic polymorphism of the tissue inhibitor of metalloproteinase-1 is associated with an increased risk of endometrial cancer. Clin Chim Acta 409:127–131
Zhou Y, Yu C, Miao X, Tan W, Liang G, Xiong P, Sun T, Lin D (2004) Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 25:399–404
Acknowledgments
We are indebted to Mr. Yujiro Ikuta for excellent technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ikebuchi, Y., Ishida, C., Okamoto, K. et al. Association of TIMP-1 and TIMP-2 Gene Polymorphisms with Progression of Liver Fibrosis in Patients with Type C Chronic Liver Disease. Biochem Genet 51, 564–574 (2013). https://doi.org/10.1007/s10528-013-9587-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10528-013-9587-8